About: Convalescent plasma a clutch at straws in COVID‐19 management! A systematic review and meta‐analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Convalescent plasma a clutch at straws in COVID‐19 management! A systematic review and meta‐analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Convalescent plasma a clutch at straws in COVID‐19 management! A systematic review and meta‐analysis
Creator	Kapil, Dev Khanna, Puneet Sarkar, Soumya Soni, Kapil Soni,
Source	Medline; PMC
abstract	BACKGROUND: In absence of definitive therapy for coronavirus disease (COVID‐19), convalescent plasma therapy (CPT) may be a critical therapeutic option. This review was conducted to evaluate the impact of CPT in COVID‐19 patients based on the publications reported to date. METHODS: A robust screening of electronic databases was conducted up to 10(th) July 2020. The randomized controlled trials (RCTs), cohort studies, and case series with control group evaluating the effectiveness and safety of CPT in patients with COVID‐19 are included for the meta‐analyses. RESULTS: Our search retrieved seven studies, including two RCTs and five cohort studies, with a total of 5,444 patients. In patients with COVID‐19, the use of CPT reduces mortality [Odd's ratio (OR) 0.44, 95% CI 0.25 to 0.77], increases viral clearance [OR 11.29, 95% CI 4.9 to 25.9] and improves clinically [OR 2.06, 95% CI 0.8 to 4.9].However, the evidences are of low quality (mortality reduction, and viral clearance),and very low quality (clinical improvement). CONCLUSIONS: CPT may be beneficial for reducing mortality, viral shedding. and improving clinical conditions in COVID‐19 patients. However, further randomized control trials (RCT) are required to substantiate the safety margin, initiation, optimal dosage, titre and duration of CPT. This article is protected by copyright. All rights reserved.
has issue date	2020-08-10(xsd:dateTime)
bibo:doi	10.1002/jmv.26408
bibo:pmid	32776573
has license	no-cc
sha1sum (hex)	1ec93c150e850cd666e0e09c25cf4adf23eb96cc
schema:url	https://doi.org/10.1002/jmv.26408
resource representing a document's title	Convalescent plasma a clutch at straws in COVID‐19 management! A systematic review and meta‐analysis
has PubMed Central identifier	PMC7436491
has PubMed identifier	32776573
schema:publication	J Med Virol
resource representing a document's body	covid:1ec93c150e850cd666e0e09c25cf4adf23eb96cc#body_text
is schema:about of	named entity 'systematic review' named entity 'COVID' named entity 'meta-analysis' named entity 'COVID-19' named entity 'control group' named entity 'COVID-19' named entity 'COVID -19' named entity 'case series' named entity 'PRISMA' named entity 'cohort studies' named entity 'publication bias' named entity '95% confidence interval' named entity 'dichotomous' named entity 'COVID-19' named entity 'missing data' named entity 'COVID-19' named entity 'statistically significant' named entity 'convalescent plasma therapy' named entity 'cohort studies' named entity 'outcome data' named entity 'COVID-19' named entity 'transfusion' named entity 'RCTs' named entity 'confounding' named entity 'meta-analysis' named entity 'decision making' named entity 'severe acute respiratory syndrome' named entity 'convalescent plasma' named entity 'case-control studies' named entity 'COVID-19' named entity 'SARS-CoV-2' named entity 'SARS' named entity 'viral shedding' named entity 'statistically significant' named entity 'confidence intervals' named entity 'Funnel plot' named entity 'RCTs' named entity 'systematic review' named entity 'publication bias' named entity 'publication bias' named entity '5.4' named entity 'randomization' named entity 'plasma' named entity 'cross-sectional studies' named entity 'dose-response' named entity 'control groups' named entity 'systematic review' named entity 'confounders' named entity 'data extraction' named entity 'COVID-19' named entity 'RCT' named entity 'cohort studies' named entity 'GRADE' named entity 'randomized Studies' named entity 'randomized studies' named entity 'public health' named entity 'systematic review' named entity 'COVID-19' named entity 'publication bias' named entity 'clinical symptoms' named entity 'Funnel plot' named entity 'meta-analysis' named entity 'placebo' named entity 'randomized controlled trials' named entity 'controlled clinical trials' named entity 'steroid' named entity '19 management' named entity 'coronavirus disease' named entity 'Convalescent plasma' named entity 'COVID' named entity 'DEFINITIVE THERAPY' named entity 'ACCEPTED' named entity 'MANAGEMENT' named entity 'definitive therapy' named entity 'coronavirus' named entity 'disease' named entity 'meta-analysis'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software